Vantage logo

No buyout for Uniqure

But a licensing deal with CSL could have underappreciated benefits, even if expectations were for something much bigger.

Vantage logo

New Pfizer, same problem

Pfizer’s chief executive has pledged to throw money at the pharma giant’s thin pipeline and shirk financial engineering, but only canny deal-making will keep investors on…

Vantage logo

Ash 2019 winners and losers

Data and M&A lifts buoyant biopharma companies from Fate Therapeutics to Rocket, though on share price gain Forty Seven wins Ash 2019.